none13Conventional chemotherapeutic regimens have reached an efficacy plateau against most solid tumors and deal with significant toxicity. Recently, the goal of oncologic research to improve outcome and reduce treatment-related side-effects has led to the development of novel anticancer treatments targeting specific proteins or genes involved in cancer growth and progression. In particular, the tyrosine- kinase inhibitors (TKIs) gefitinib and erlotinib targeting the epidermal growth factor receptor (EGFR) have been approved for the treatment of non-small-cell lung cancer (NSCLC). Their clinical activity has been related to different clinical and biological parameters, such as the presence of activating mutations in the kinase domain of the...
Tumor molecular profiling in patients with non-small cell lung cancer (NSCLC) is used to identify dr...
Tyrosine kinase inhibitors (TKIs) against human epidermal growth factor receptor (EGFR/HER) family h...
AbstractThe development of orally active small molecule inhibitors of the epidermal growth factor re...
none13Conventional chemotherapeutic regimens have reached an efficacy plateau against most solid tum...
In the last decade, better understanding of the role of epidermal growth factor receptor in the path...
In the last decade, better understanding of the role of epidermal growth factor receptor in the path...
SummaryTwo classes of epidermal growth factor receptor (EGFR) inhibitors are currently available for...
In non-small cell lung cancer (NSCLC), the identification of epidermal growth factor receptor (EGFR)...
SummaryTwo classes of epidermal growth factor receptor (EGFR) inhibitors are currently available for...
Gefitinib and erlotinib, small-molecule tyrosine kinase inhibitors (TKIs) of the epidermal growth fa...
The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small Cell Lung Cancer (NS...
The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small Cell Lung Cancer (NS...
The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small Cell Lung Cancer (NS...
The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small Cell Lung Cancer (NS...
Since the discovery of sensitizing EGFR mutations as a predictive marker of sensitivity to EGFR tyro...
Tumor molecular profiling in patients with non-small cell lung cancer (NSCLC) is used to identify dr...
Tyrosine kinase inhibitors (TKIs) against human epidermal growth factor receptor (EGFR/HER) family h...
AbstractThe development of orally active small molecule inhibitors of the epidermal growth factor re...
none13Conventional chemotherapeutic regimens have reached an efficacy plateau against most solid tum...
In the last decade, better understanding of the role of epidermal growth factor receptor in the path...
In the last decade, better understanding of the role of epidermal growth factor receptor in the path...
SummaryTwo classes of epidermal growth factor receptor (EGFR) inhibitors are currently available for...
In non-small cell lung cancer (NSCLC), the identification of epidermal growth factor receptor (EGFR)...
SummaryTwo classes of epidermal growth factor receptor (EGFR) inhibitors are currently available for...
Gefitinib and erlotinib, small-molecule tyrosine kinase inhibitors (TKIs) of the epidermal growth fa...
The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small Cell Lung Cancer (NS...
The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small Cell Lung Cancer (NS...
The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small Cell Lung Cancer (NS...
The discovery of Epidermal Growth Factor Receptor (EGFR) mutations in Non Small Cell Lung Cancer (NS...
Since the discovery of sensitizing EGFR mutations as a predictive marker of sensitivity to EGFR tyro...
Tumor molecular profiling in patients with non-small cell lung cancer (NSCLC) is used to identify dr...
Tyrosine kinase inhibitors (TKIs) against human epidermal growth factor receptor (EGFR/HER) family h...
AbstractThe development of orally active small molecule inhibitors of the epidermal growth factor re...